Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

OBJECTIVE: The aim of this study was to compare healthcare costs between ixekizumab (IXE)-treated and secukinumab (SEC)-treated patients with psoriasis over a 24-month follow-up period in the United States. METHODS: Patients with psoriasis diagnosis were identified from IBM Watson Health MarketScan(...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Atiya, Bilal, Zhu, Baojin, Somani, Najwa, Ridenour, Terri, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596621/
https://www.ncbi.nlm.nih.gov/pubmed/36155891
http://dx.doi.org/10.1007/s41669-022-00365-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596621/
https://www.ncbi.nlm.nih.gov/pubmed/36155891
http://dx.doi.org/10.1007/s41669-022-00365-z

Ejemplares similares